iOrganBio, an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs), today announced the appointment of Jessica Owens to its Board of Directors. Owens is a seasoned venture investor and serial founder with extensive experience building and scaling companies at the intersection of life sciences, health technology and AI.
Owens brings over 20 years of company-building and investing experience, including co-founding GRAIL, which raised over $1B and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serving as co-founder and General Partner at Initiate Ventures. iOrganBio says her counsel will be invaluable as it scales CellForge, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies.
iOrganBio is transforming human cell production with CellForge, its AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
The appointment of Jessica Owens signals iOrganBio's commitment to scaling its operations and integrating AI-driven solutions in the life sciences sector. Her experience in building high-growth companies and fostering strategic partnerships will be critical as iOrganBio looks to expand its footprint in the cell therapy and drug development markets. For more information, visit iOrgan.Bio or follow us on LinkedIn. The full announcement, including downloadable images and bios, is available here.
